Quantifying the effects of prior acetyl-salicylic acid on sepsis-related deaths: An individual patient data meta-analysis using propensity matching

Critical Care Medicine

Volumn 45, Issue 11, 2017, Pages 1871-1879

  Trauer, James ^a   Muhi, Stephen ^b   McBryde, Emma S ^b,c   Al Harbi, Shmeylan A ^d   Arabi, Yaseen M ^e   Boyle, Andrew J ^f   Cartin Ceba, Rodrigo ^g   Chen, Wei ^h   Chen, Yung Tai ⁱ   Falcone, Marco ^j   Gajic, Ognjen ^g   Godsell, Jack ^b   Gong, Michelle Ng ^k,l   Kor, Daryl ^g   Lösche, Wolfgang ^m   McAuley, Daniel F ⁿ   O'Neal, Hollis R ^o   Osthoff, Michael ^p   Otto, Gordon P ^m   Sossdorf, Maik ^m   Tsai, Min Juei ^q   Valerio Rojas, Juan C ^g,r   Van Der Poll, Tom ^s   Violi, Francesco ^t   Ware, Lorraine ^u   Widmer, Andreas F ^p   Wiewel, Maryse A ^s   Winning, Johannes ^m   Eisen, Damon P ^b,c,v   more..

^a MONASH UNIVERSITY   (Australia)

^b PETER DOHERTY INSTITUTE FOR INFECTION AND IMMUNITY   (Australia)

^c JAMES COOK UNIVERSITY   (Australia)

^d KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^e KING SAUD BIN ABDULAZIZ UNIVERSITY FOR HEALTH SCIENCES   (Saudi Arabia)

^f ROYAL VICTORIA HOSPITAL   (United Kingdom)

^g MAYO CLINIC   (United States)

^h CHIA YI CHRISTIAN HOSPITAL   (Taiwan)

ⁱ TAIPEI CITY HOSPITAL   (Taiwan)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k MONTEFIORE MEDICAL CENTER   (United States)

^l ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^m JENA UNIVERSITY HOSPITAL   (Germany)

ⁿ QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^o LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^p UNIVERSITY HOSPITAL BASEL   (Switzerland)

^q TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^r Hospital San Rafael   (Costa Rica)

^s UNIVERSITY OF AMSTERDAM   (Netherlands)

^t SAPIENZA UNIVERSITY OF ROME   (Italy)

^u VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^v TOWNSVILLE HOSPITAL   (Australia)

more..

Author keywords

Acetyl salicylic acid; Aspirin; Death; Mortality; Sepsis

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT;

APACHE; ARTICLE; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; COMORBIDITY; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEATH; DIABETES MELLITUS; HEALTH INSURANCE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; META ANALYSIS; MORTALITY; MORTALITY RISK; PRIORITY JOURNAL; PROPENSITY SCORE; RISK FACTOR; RISK REDUCTION; SEPSIS; SYSTEMATIC REVIEW; AGED; FEMALE; MALE; MIDDLE AGED; OBSERVATIONAL STUDY;

AGED; ASPIRIN; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; SEPSIS;

EID: 85032159686     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000002654     Document Type: Article

References (40)

1. Cohen J, Vincent JL, Adhikari NK, et al: Sepsis: A roadmap for future research. Lancet Infect Dis 2015; 15:581-614
2. Kaukonen KM, Bailey M, Suzuki S, et al: Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014; 311:1308-1316
3. Kadri SS, Rhee C, Strich JR, et al: Estimating ten-year trends in septic shock incidence and mortality in United States academic medical centers using clinical data. Chest 2017; 151:278-285
4. Winning J, Reichel J, Eisenhut Y, et al: Anti-platelet drugs and outcome in severe infection: Clinical impact and underlying mechanisms. Platelets 2009; 20:50-57
5. Winning J, Neumann J, Kohl M, et al: Antiplatelet drugs and outcome in mixed admissions to an intensive care unit. Crit Care Med 2010; 38:32-37
6. Lösche W, Boettel J, Kabisch B, et al: Do aspirin and other antiplatelet drugs reduce the mortality in critically ill patients? Thrombosis 2012; 2012:720254
7. O'Neal HR Jr, Koyama T, Koehler EA, et al: Prehospital statin and aspirin use and the prevalence of severe sepsis and acute lung injury/acute respiratory distress syndrome. Crit Care Med 2011; 39:1343-1350
8. Eisen DP, Reid D, McBryde ES: Acetyl salicylic acid usage and mortality in critically ill patients with the systemic inflammatory response syndrome and sepsis. Crit Care Med 2012; 40:1761-1767
9. Otto GP, Sossdorf M, Boettel J, et al: Effects of low-dose acetylsalicylic acid and atherosclerotic vascular diseases on the outcome in patients with severe sepsis or septic shock. Platelets 2013; 24:480-485
10. Valerio-Rojas JC, Jaffer IJ, Kor DJ, et al: Outcomes of severe sepsis and septic shock patients on chronic antiplatelet treatment: A historical cohort study. Crit Care Res Pract 2013; 2013:782573
11. Boyle AJ, Di Gangi S, Hamid UI, et al: Aspirin therapy in patients with acute respiratory distress syndrome (ARDS) is associated with reduced intensive care unit mortality: A prospective analysis. Crit Care 2015; 19:109
12. Falcone M, Russo A, Cangemi R, et al: Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin. J Am Heart Assoc 2015; 4:e001595
13. Tsai MJ, Ou SM, Shih CJ, et al: Association of prior antiplatelet agents with mortality in sepsis patients: A nationwide population-based cohort study. Intensive Care Med 2015; 41:806-813
14. Al Harbi SA, Tamim HM, Al-Dorzi HM, et al: Association between aspirin therapy and the outcome in critically ill patients: A nested cohort study. BMC Pharmacol Toxicol 2016; 17:5
15. Osthoff M, Sidler JA, Lakatos B, et al: Low-dose acetylsalicylic acid treatment and impact on short-term mortality in Staphylococcus aureus bloodstream infection: A propensity score-matched cohort study. Crit Care Med 2016; 44:773-781
16. Wiewel MA, de Stoppelaar S F, van Vught LA, et al; MARS Consortium: Chronic antiplatelet therapy is not associated with alterations in the presentation, outcome, or host response biomarkers during sepsis: A propensity-matched analysis. Intensive Care Med 2016; 42:352-360
17. Kor DJ, Erlich J, Gong MN, et al; U.S. Critical Illness and Injury Trials Group: Lung Injury Prevention Study Investigators: Association of prehospitalization aspirin therapy and acute lung injury: Results of a multicenter international observational study of at-risk patients. Crit Care Med 2011; 39:2393-2400
18. Erlich JM, Talmor DS, Cartin-Ceba R, et al: Prehospitalization anti-platelet therapy is associated with a reduced incidence of acute lung injury: A population-based cohort study. Chest 2011; 139:289-295
19. Chen W, Janz DR, Bastarache JA, et al: Prehospital aspirin use is associated with reduced risk of acute respiratory distress syndrome in critically ill patients: A propensity-adjusted analysis. Crit Care Med 2015; 43:801-807
20. Stroup DF, Berlin JA, Morton SC, et al: Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012
21. Sossdorf MOG, Boettel J, Winning J, et al: Benefit of low-dose aspirin and non-steroidal anti-inflammatory drugs in septic patients. Crit Care 2013; 17:1-2
22. Serhan CN, Chiang N: Lipid-derived mediators in endogenous anti-inflammation and resolution: Lipoxins and aspirin-triggered 15-epilipoxins. Scientific World Journal 2002; 2:169-204
23. Kopp E, Ghosh S: Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 1994; 265:956-959
24. Serhan CN, Haeggström JZ, Leslie CC: Lipid mediator networks in cell signaling: Update and impact of cytokines. FAS E B J 1996; 10:1147-1158
25. Arita M, Yoshida M, Hong S, et al: Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 2005; 102:7671-7676
26. Paul-Clark MJ, Van Cao T, Moradi-Bidhendi N, et al: 15-epi-lipoxin A4-mediated induction of nitric oxide explains how aspirin inhibits acute inflammation. J Exp Med 2004; 200:69-78
27. Chiang N, Bermudez EA, Ridker PM, et al: Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc Natl Acad Sci U S A 2004; 101:15178-15183
28. El Kebir D, József L, Pan W, et al: 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am J Respir Crit Care Med 2009; 180:311-319
29. Hennekens CH, Schneider WR, Pokov A, et al: A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans. J Cardiovasc Pharmacol Ther 2010; 15:344-348
30. Morris T, Stables M, Hobbs A, et al: Effects of low-dose aspirin on acute inflammatory responses in humans. J Immunol 2009; 183:2089-2096
31. Cox D, Kerrigan SW, Watson SP: Platelets and the innate immune system: Mechanisms of bacterial-induced platelet activation. J Thromb Haemost 2011; 9:1097-1107
32. Masotti G, Galanti G, Poggesi L, et al: Differential inhibition of prostacyclin production and platelet aggregation by aspirin in humans. Adv Prostaglandin Thromboxane Res 1980; 6:317-320
33. Carvalho-Tavares J, Hickey MJ, Hutchison J, et al: A role for platelets and endothelial selectins in tumor necrosis factor-alpha-induced leukocyte recruitment in the brain microvasculature. Circ Res 2000; 87:1141-1148
34. Patrono C, García Rodríguez LA, Landolfi R, et al: Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383
35. Kor DJ, Carter RE, Park PK, et al; US Critical Illness and Injury Trials Group: Lung Injury Prevention with Aspirin Study Group (USCIITG: LIPS-A): Effect of aspirin on development of ARDS in at-risk patients presenting to the emergency department: The LIPS-A randomized clinical trial. JAMA 2016; 315:2406-2414
36. Bone RC, Balk RA, Cerra FB, et al: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101:1644-1655
37. Levy MM, Fink MP, Marshall JC, et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29:530-538
38. Singer M, Deutschman CS, Seymour CW, et al: The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA 2016; 315:801-810
39. Seshasai SR, Wijesuriya S, Sivakumaran R, et al: Effect of aspirin on vascular and nonvascular outcomes: Meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209-216
40. Nelson MR, Reid CM, Ames DA, et al: Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: Results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust 2008; 189:105-109